Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ADVANCE-CIDP 3

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

The phase 3 results show improvements in daily function, cognition and nighttime sleep

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

- PMLiVE

EC approves argenx’s subcutaneous Vyvgart for rare autoimmune disease CIPD

The drug has been authorised as a monotherapy for adults with progressive or relapsing active cases

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

- PMLiVE

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

- PMLiVE

Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

Around 800 people in the UK are diagnosed with late-stage disease every year

- PMLiVE

Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

Up to 160,000 people in the US are affected by polycythaemia vera

- PMLiVE

Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

Approximately three million people in Europe are affected by inflammatory bowel disease

- PMLiVE

WHO calls for better medicines access to close neurological disorders treatment gap

In 2021, neurological conditions affected more than three billion people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links